Brokerages expect that Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) will report $1.56 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Tetraphase Pharmaceuticals’ earnings, with the highest sales estimate coming in at $1.88 million and the lowest estimate coming in at $1.30 million. Tetraphase Pharmaceuticals posted sales of $1.24 million during the same quarter last year, which suggests a positive year-over-year growth rate of 25.8%. The firm is expected to report its next quarterly earnings report on Thursday, August 3rd.
According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year sales of $1.56 million for the current year, with estimates ranging from $4.99 million to $7.11 million. For the next financial year, analysts forecast that the company will report sales of $5.13 million per share, with estimates ranging from $3.00 million to $7.51 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported ($0.79) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.60) by $0.19. Tetraphase Pharmaceuticals had a negative net margin of 1,932.24% and a negative return on equity of 60.55%. The company had revenue of $1.48 million for the quarter, compared to analyst estimates of $1.46 million. During the same period in the prior year, the company earned ($0.46) EPS. The company’s revenue was down 24.5% compared to the same quarter last year.
A number of equities research analysts have weighed in on TTPH shares. BMO Capital Markets reaffirmed a “buy” rating and issued a $12.00 target price on shares of Tetraphase Pharmaceuticals in a report on Friday, May 5th. Zacks Investment Research downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. Finally, HC Wainwright started coverage on Tetraphase Pharmaceuticals in a report on Tuesday. They issued a “buy” rating and a $15.00 target price on the stock. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Tetraphase Pharmaceuticals has an average rating of “Hold” and a consensus price target of $8.45.
Several large investors have recently added to or reduced their stakes in TTPH. UBS Group AG increased its stake in Tetraphase Pharmaceuticals by 2.3% in the first quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 387 shares during the period. Teza Capital Management LLC increased its stake in Tetraphase Pharmaceuticals by 8.9% in the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 1,281 shares during the period. Federated Investors Inc. PA increased its stake in Tetraphase Pharmaceuticals by 1.0% in the fourth quarter. Federated Investors Inc. PA now owns 130,809 shares of the biopharmaceutical company’s stock valued at $527,000 after buying an additional 1,326 shares during the period. American International Group Inc. increased its stake in Tetraphase Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 22,390 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,486 shares during the period. Finally, Citadel Advisors LLC increased its stake in Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 2,496 shares during the period. 47.77% of the stock is currently owned by institutional investors.
Tetraphase Pharmaceuticals (TTPH) opened at 7.80 on Friday. The stock’s 50 day moving average is $7.48 and its 200-day moving average is $6.43. Tetraphase Pharmaceuticals has a 1-year low of $3.11 and a 1-year high of $9.93. The firm’s market cap is $296.06 million.
COPYRIGHT VIOLATION NOTICE: “Analysts Expect Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Will Announce Quarterly Sales of $1.56 Million” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://transcriptdaily.com/2017/07/15/analysts-expect-tetraphase-pharmaceuticals-inc-nasdaqttph-will-announce-quarterly-sales-of-1-56-million.html.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.